PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors.

IF 9 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

EMBO Molecular Medicine Pub Date : 2025-07-21 DOI:10.1038/s44321-025-00277-5

Chiara Pozzi,Riccardo Sarti,Antonino Lo Cascio,Stefanos Bonovas,Luca Tiraboschi,Michela Lizier,Alice Bertocchi,Rosalba Torrisi,Bethania Fernandes,Piergiuseppe Colombo,Pietro Diana,Emilia Maria Cristina Mazza,Marina Valeri,Salvatore Lorenzo Renne,Ferdinando Carlo Maria Cananzi,Laura Samà,Alexia Bertuzzi,Corrado Tinterri,Massimo Lazzeri,Maria Rescigno

{"title":"PV-1: a novel molecular prognostic marker of distant metastases in various solid tumors.","authors":"Chiara Pozzi,Riccardo Sarti,Antonino Lo Cascio,Stefanos Bonovas,Luca Tiraboschi,Michela Lizier,Alice Bertocchi,Rosalba Torrisi,Bethania Fernandes,Piergiuseppe Colombo,Pietro Diana,Emilia Maria Cristina Mazza,Marina Valeri,Salvatore Lorenzo Renne,Ferdinando Carlo Maria Cananzi,Laura Samà,Alexia Bertuzzi,Corrado Tinterri,Massimo Lazzeri,Maria Rescigno","doi":"10.1038/s44321-025-00277-5","DOIUrl":null,"url":null,"abstract":"Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel permeability and is an independent predictor of colorectal cancer dissemination. This study investigates whether PV-1 can also act as a prognostic marker for distant metastases in other solid tumors. We analyzed samples from 134 patients: 30 luminal breast cancer (BC), 52 clear cell renal cell carcinoma (ccRCC), and obtained preliminary data from 52 soft tissue sarcomas (STS). A higher frequency of PV-1+ endothelial cells was significantly associated with metastatic progression in luminal BC and ccRCC. Moreover, the frequency of PV-1+ cells emerged as a significant prognostic factor for metastasis-free survival in both luminal BC and ccRCC. Further research is needed to validate PV-1's prognostic utility, as including it at diagnosis may change the management of these patients and should allow stratification for more aggressive therapies or for closer follow-ups to promptly intervene in case of metastases development.","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":"6 1","pages":""},"PeriodicalIF":9.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-025-00277-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel permeability and is an independent predictor of colorectal cancer dissemination. This study investigates whether PV-1 can also act as a prognostic marker for distant metastases in other solid tumors. We analyzed samples from 134 patients: 30 luminal breast cancer (BC), 52 clear cell renal cell carcinoma (ccRCC), and obtained preliminary data from 52 soft tissue sarcomas (STS). A higher frequency of PV-1+ endothelial cells was significantly associated with metastatic progression in luminal BC and ccRCC. Moreover, the frequency of PV-1+ cells emerged as a significant prognostic factor for metastasis-free survival in both luminal BC and ccRCC. Further research is needed to validate PV-1's prognostic utility, as including it at diagnosis may change the management of these patients and should allow stratification for more aggressive therapies or for closer follow-ups to promptly intervene in case of metastases development.

查看原文本刊更多论文

PV-1：各种实体瘤远处转移的新分子预后标志物。

鉴别肿瘤细胞血液扩散的生物标志物具有重要的预后和治疗价值。我们发现，质膜囊泡相关蛋白-1 （PV-1）是血管通透性增加的标志，是结直肠癌传播的独立预测因子。本研究探讨PV-1是否也可以作为其他实体瘤远处转移的预后标志物。我们分析了134例患者的样本：30例腔内乳腺癌（BC）， 52例透明细胞肾细胞癌（ccRCC），并获得了52例软组织肉瘤（STS）的初步数据。更高频率的PV-1+内皮细胞与腔内BC和ccRCC的转移进展显著相关。此外，PV-1+细胞的出现频率是腔内BC和ccRCC无转移生存的重要预后因素。需要进一步的研究来验证PV-1的预后效用，因为在诊断时包含PV-1可能会改变这些患者的管理，并且应该允许分层进行更积极的治疗或更密切的随访，以便在转移发展时及时干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EMBO Molecular Medicine 医学-医学：研究与实验

CiteScore

17.70

自引率

0.90%

发文量

105

审稿时长

4-8 weeks

期刊介绍： EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance. To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields: Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention). Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease. Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)